{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"15.1","upperLimit":"25.8","value":"18.4"},{"comment":"The upper limit of 95% CI was not estimable due to insufficient number of participants with events.","groupId":"OG001","lowerLimit":"40.0","upperLimit":"NA","value":"51.8"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"22"},{"groupId":"OG001","value":"32"}],"units":"Participants"}],"title":"M918T"},{"categories":[{"measurements":[{"comment":"The upper limit of 95% CI was not estimable due to insufficient number of participants with events.","groupId":"OG000","lowerLimit":"8.8","upperLimit":"NA","value":"29.5"},{"comment":"The upper limit of 95% CI was not estimable due to insufficient number of participants with events.","groupId":"OG001","lowerLimit":"23.1","upperLimit":"NA","value":"36.8"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"22"}],"units":"Participants"}],"title":"Cysteine Rich Domain"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"14.2","upperLimit":"29.4","value":"21.8"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"0"}],"units":"Participants"}],"title":"V804X"},{"categories":[{"measurements":[{"comment":"The median and upper limit of 95% CI was not estimable due to insufficient number of participants with events.","groupId":"OG000","lowerLimit":"14.5","upperLimit":"NA","value":"NA"},{"comment":"The median and 95% CI was not estimable due to insufficient number of participants with events.","groupId":"OG001","lowerLimit":"NA","upperLimit":"NA","value":"NA"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"2"}],"units":"Participants"}],"title":"Other"}],"denoms":[{"counts":[{"groupId":"OG000","value":"34"},{"groupId":"OG001","value":"56"}],"units":"Participants"}],"description":"Oncogenic RET activation has been implicated as a driver in MTC. These rearrangements typically produce chimeric transcripts that encode a fusion protein consisting of the RET kinase domain coupled to a protein with a dimerization domain (e.g., M918T, cysteine rich domain, V804X). RET genotypes were determined by local testing and/or central analysis of ctDNA. DOR was assessed in participants having specific RET rearrangements. DOR=time from first documented CR/PR to date of first documented PD or death due to any cause, whichever occurs first. Per RECIST, CR= disappearance of all target lesions or any pathological lymph nodes (target or non-target) having a reduction in the short axis to \\<10 mm. PR=at least a 30% decrease in the SOD of all target lesions, taking as reference the baseline SOD, in absence of CR. PD=as at least a 20% increase in SOD of target lesions, taking as reference smallest SOD on study (including baseline). DOR was analyzed using the Kaplan-Meier (KM) method.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants who had RET- mutation positive MTC previously treated with either cabozantinib and/or vandetanib therapies received pralsetinib, 400 mg orally, QD until discontinuation due to toxicity, disease progression, or other reasons.","id":"OG000","title":"RET-mutation MTC With Prior Cabozantinib and/or Vandetanib Treatment"},{"description":"Participants who had RET- mutation positive MTC not previously treated with cabozantinib or vandetanib therapies received pralsetinib, 400 mg orally, QD until discontinuation due to toxicity, disease progression, or other reasons.","id":"OG001","title":"RET-mutation MTC With No Prior Cabozantinib or Vandetanib Treatment"}],"paramType":"MEDIAN","populationDescription":"RET-altered measurable disease population included participants in the efficacy population who have measurable (target) disease per RECIST v1.1, at baseline according to BICR \\& sufficient evidence of a RET alteration. As prespecified in SAP, Phase 1 participants treated at 400 mg QD are pooled with Phase 2 participants for efficacy analysis. Participants who had a response of CR/PR were analyzed in this outcome measure. Number analyzed is the number of participants with the specified mutation.","reportingStatus":"POSTED","timeFrame":"Up to approximately 79.8 months","title":"Phase 1 and Phase 2: DOR in RET-mutation MTC Participants With Specific RET Gene Status","type":"SECONDARY","unitOfMeasure":"months"}